KPV peptide: what the research shows
KPV is one of the smallest peptides studied for inflammation: just three amino acids, lysine, proline and valine. It is the tail end of alpha-melanocyte-stimulating hormone (α-MSH), a hormone known for its anti-inflammatory effects, and most of the research on it concerns inflammation of the gut. This guide covers where KPV comes from, how it is thought to work, what the animal studies found and what remains unproven.
At a glance
| KPV | |
|---|---|
| Sequence | Lys-Pro-Val (3 amino acids) |
| Origin | Positions 11–13 of α-MSH, the C-terminal end of the hormone |
| Main research area | Intestinal inflammation (mouse colitis models) |
| Proposed mechanism | Reduced inflammatory signalling (NF-κB) inside cells; uptake in the gut through the PepT1 transporter |
| Effect on pigmentation | None reported: it lacks the part of α-MSH that drives skin darkening |
| Routes studied | Oral (drinking water, nanoparticles) and injection in animals |
| Human trials | None published |
From α-MSH to KPV
α-MSH is a 13-amino-acid hormone cut from a larger precursor, pro-opiomelanocortin. It is best known for stimulating melanin production in the skin, but it also damps down inflammation, which led researchers to look for the part of the molecule responsible.
The pigment effect depends on the central section of α-MSH (His-Phe-Arg-Trp), which binds the melanocortin receptors on pigment cells. KPV, the last three amino acids, does not contain this section. Reviews of the field report that it keeps much of the hormone's anti-inflammatory activity while showing no pigmentary action, which is what made it interesting as a separate compound.
How it is thought to work
- Inflammatory signalling: α-MSH and its C-terminal tripeptides reduce activation of NF-κB, a master switch that turns on inflammatory genes, in several cell types.
- Not only through melanocortin receptors: in mice whose MC1 receptor does not work, KPV still protected against induced colitis. The authors concluded its effects are at least partly independent of that receptor.
- Uptake by PepT1: PepT1 is a transporter that moves small peptides from food into intestinal cells. Its levels rise in inflamed colon tissue. KPV is a PepT1 substrate, so it can be carried into the very cells involved in gut inflammation, at low concentrations.
Gut research
Most of the published work uses mouse models of colitis, where inflammation is triggered chemically (DSS or TNBS) or by transferring immune cells:
- Oral KPV via PepT1 (2008): KPV given in drinking water reduced the severity of both DSS- and TNBS-induced colitis, with lower levels of inflammatory cytokines in the colon. The study also showed that intestinal and immune cells take KPV up through PepT1.
- Two colitis models and MC1R (2008): KPV speeded recovery and weight regain and reduced inflammatory cell infiltration in DSS colitis and in T-cell transfer colitis. In mice without a working MC1 receptor, all KPV-treated animals survived DSS colitis.
- Targeted nanoparticles (2017): KPV loaded into nanoparticles coated with hyaluronic acid, which binds the CD44 receptor overexpressed in inflamed colon tissue, and given orally inside a hydrogel, protected the colon lining and lowered TNF-α in mice more effectively than free KPV.
Together these make the gut the most consistent area of KPV research. All of it, however, is in mice and in cells.
Skin and antimicrobial claims
A 2000 study reported that α-MSH peptides containing the KPV sequence, including KPV itself, reduced the growth of Staphylococcus aureus and Candida albicans in laboratory tests. This is often repeated as "KPV is antimicrobial". The evidence is weaker than that suggests: later testing under standard laboratory methods found no measurable minimum inhibitory concentration for KPV against S. aureus, E. coli or yeast at up to 2000 µg/ml. Clear antimicrobial activity only appeared once fatty-acid chains were attached to the peptide, which makes it a different molecule.
Claims online about completed human trials of KPV creams for psoriasis or other skin conditions could not be traced to any published study or trial registry entry.
Why capsules, and why combined with BPC-157
Because KPV is taken up by PepT1 in the intestine and the key studies gave it by mouth, oral forms are a natural fit for gut-focused research. Capsules also avoid reconstitution and keep the peptide dry.
KPV is sometimes combined with BPC-157 arginate, another peptide studied orally for the gut, so both reach the same tissue in one preparation. We are not aware of any published study of the combination itself; the rationale comes from the separate literature on each. For the BPC-157 side, see BPC-157 arginate vs acetate.
What is not known
- Human data: no controlled human trial of KPV has been published.
- Absorption: how much KPV reaches the bloodstream after oral dosing, and how long it lasts, has not been measured in published pharmacokinetic studies.
- Independent replication: the colitis findings come from a small number of groups and have not been tested against standard treatments.
Regulatory status
KPV is not approved as a medicine in the EU, the UK or the US. It is sold for laboratory research only.
Handling
Vials of KPV are lyophilised powder and are stored like other research peptides: unopened vials in the freezer, reconstituted solutions in the refrigerator. Capsules should be kept closed, cool and dry. See our storage guide for details.
References
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134(1):166–178.
- Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008;14(3):324–331.
- Xiao B et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther 2017;25(7):1628–1640.
- Brzoska T et al. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 2008;29(5):581–602.
- Cutuli M et al. Antimicrobial effects of α-MSH peptides. J Leukoc Biol 2000;67(2):233–239.
- Short antimicrobial lipopeptides. US Patent 9,278,994 (2016).